Selected research
Industry Research
Doxorubicin Injection Industry Research Report 2026
Market perspective
The global Doxorubicin Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Doxorubicin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Doxorubicin Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Doxorubicin Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Doxorubicin Injection include Teva, Mylan, Pfizer, Fresenius Kabi, TAJ Pharma, Sagent, Hikma, Getwell Pharma and AdvaCare Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Doxorubicin Injection market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Doxorubicin Injection Market by Company
Teva
Mylan
Pfizer
Fresenius Kabi
TAJ Pharma
Sagent
Hikma
Getwell Pharma
AdvaCare Pharma
Doxorubicin Injection Segment by Type
5ml/vial
10ml/vial
50ml/vial
Doxorubicin Injection Segment by Application
Hospital
Clinics
Others
Doxorubicin Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Doxorubicin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Doxorubicin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Doxorubicin Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Doxorubicin Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Doxorubicin Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Doxorubicin Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 5ml/vial
- 10ml/vial
- 50ml/vial
Applications
- Hospital
- Clinics
- Others
Companies covered
- Teva
- Mylan
- Pfizer
- Fresenius Kabi
- TAJ Pharma
- Sagent
- Hikma
- Getwell Pharma
- AdvaCare Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Doxorubicin Injection Market Size (2021-2032)
- 2.2.2 Global Doxorubicin Injection Sales (2021-2032)
- 2.2.3 Global Doxorubicin Injection Market Average Price (2021-2032)
- 2.3 Doxorubicin Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 5ml/vial
- 2.3.3 10ml/vial
- 2.3.4 50ml/vial
- 2.4 Doxorubicin Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinics
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Doxorubicin Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Doxorubicin Injection Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Doxorubicin Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Doxorubicin Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Doxorubicin Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Doxorubicin Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Doxorubicin Injection, Product Type & Application
- 3.8 Global Manufacturers of Doxorubicin Injection, Established Date
- 3.9 Global Doxorubicin Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Doxorubicin Injection Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Mylan
- 4.2.1 Mylan Company Information
- 4.2.2 Mylan Business Overview
- 4.2.3 Mylan Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Doxorubicin Injection Product Portfolio
- 4.2.5 Mylan Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Doxorubicin Injection Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Fresenius Kabi
- 4.4.1 Fresenius Kabi Company Information
- 4.4.2 Fresenius Kabi Business Overview
- 4.4.3 Fresenius Kabi Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Fresenius Kabi Doxorubicin Injection Product Portfolio
- 4.4.5 Fresenius Kabi Recent Developments
- 4.5 TAJ Pharma
- 4.5.1 TAJ Pharma Company Information
- 4.5.2 TAJ Pharma Business Overview
- 4.5.3 TAJ Pharma Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 TAJ Pharma Doxorubicin Injection Product Portfolio
- 4.5.5 TAJ Pharma Recent Developments
- 4.6 Sagent
- 4.6.1 Sagent Company Information
- 4.6.2 Sagent Business Overview
- 4.6.3 Sagent Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sagent Doxorubicin Injection Product Portfolio
- 4.6.5 Sagent Recent Developments
- 4.7 Hikma
- 4.7.1 Hikma Company Information
- 4.7.2 Hikma Business Overview
- 4.7.3 Hikma Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hikma Doxorubicin Injection Product Portfolio
- 4.7.5 Hikma Recent Developments
- 4.8 Getwell Pharma
- 4.8.1 Getwell Pharma Company Information
- 4.8.2 Getwell Pharma Business Overview
- 4.8.3 Getwell Pharma Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Getwell Pharma Doxorubicin Injection Product Portfolio
- 4.8.5 Getwell Pharma Recent Developments
- 4.9 AdvaCare Pharma
- 4.9.1 AdvaCare Pharma Company Information
- 4.9.2 AdvaCare Pharma Business Overview
- 4.9.3 AdvaCare Pharma Doxorubicin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AdvaCare Pharma Doxorubicin Injection Product Portfolio
- 4.9.5 AdvaCare Pharma Recent Developments
5 Global Doxorubicin Injection Market Scenario by Region
- 5.1 Global Doxorubicin Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Doxorubicin Injection Sales by Region: 2021-2032
- 5.2.1 Global Doxorubicin Injection Sales by Region: 2021-2026
- 5.2.2 Global Doxorubicin Injection Sales by Region: 2027-2032
- 5.3 Global Doxorubicin Injection Revenue by Region: 2021-2032
- 5.3.1 Global Doxorubicin Injection Revenue by Region: 2021-2026
- 5.3.2 Global Doxorubicin Injection Revenue by Region: 2027-2032
- 5.4 North America Doxorubicin Injection Market Facts & Figures by Country
- 5.4.1 North America Doxorubicin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Doxorubicin Injection Sales by Country (2021-2032)
- 5.4.3 North America Doxorubicin Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Doxorubicin Injection Market Facts & Figures by Country
- 5.5.1 Europe Doxorubicin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Doxorubicin Injection Sales by Country (2021-2032)
- 5.5.3 Europe Doxorubicin Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Doxorubicin Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Doxorubicin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Doxorubicin Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Doxorubicin Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Doxorubicin Injection Market Facts & Figures by Country
- 5.7.1 South America Doxorubicin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Doxorubicin Injection Sales by Country (2021-2032)
- 5.7.3 South America Doxorubicin Injection Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Doxorubicin Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Doxorubicin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Doxorubicin Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Doxorubicin Injection Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Doxorubicin Injection Sales by Type (2021-2032)
- 6.1.1 Global Doxorubicin Injection Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Doxorubicin Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Doxorubicin Injection Revenue by Type (2021-2032)
- 6.2.1 Global Doxorubicin Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Doxorubicin Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Doxorubicin Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Doxorubicin Injection Sales by Application (2021-2032)
- 7.1.1 Global Doxorubicin Injection Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Doxorubicin Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Doxorubicin Injection Revenue by Application (2021-2032)
- 7.2.1 Global Doxorubicin Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Doxorubicin Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Doxorubicin Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Doxorubicin Injection Value Chain Analysis
- 8.1.1 Doxorubicin Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Doxorubicin Injection Production Mode & Process
- 8.2 Doxorubicin Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Doxorubicin Injection Distributors
- 8.2.3 Doxorubicin Injection Customers
9 Global Doxorubicin Injection Analyzing Market Dynamics
- 9.1 Doxorubicin Injection Industry Trends
- 9.2 Doxorubicin Injection Industry Drivers
- 9.3 Doxorubicin Injection Industry Opportunities and Challenges
- 9.4 Doxorubicin Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst